Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis.

Spillman MA, Manning NG, Dye WW, Sartorius CA, Post MD, Harrell JC, Jacobsen BM, Horwitz KB.

Cancer Res. 2010 Nov 1;70(21):8927-36. doi: 10.1158/0008-5472.CAN-10-1238. Epub 2010 Oct 19.

2.

Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.

Ciucci A, Zannoni GF, Buttarelli M, Lisi L, Travaglia D, Martinelli E, Scambia G, Gallo D.

Oncotarget. 2016 Feb 16;7(7):8155-71. doi: 10.18632/oncotarget.6943.

3.

Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.

Taylor KJ, Sims AH, Liang L, Faratian D, Muir M, Walker G, Kuske B, Dixon JM, Cameron DA, Harrison DJ, Langdon SP.

Breast Cancer Res. 2010;12(3):R39. doi: 10.1186/bcr2593. Epub 2010 Jun 22.

4.

Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III.

Finlay-Schultz J, Gillen AE, Brechbuhl HM, Ivie JJ, Matthews SB, Jacobsen BM, Bentley DL, Kabos P, Sartorius CA.

Cancer Res. 2017 Sep 15;77(18):4934-4946. doi: 10.1158/0008-5472.CAN-16-3541. Epub 2017 Jul 20.

PMID:
28729413
5.

High levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance.

Simpson NE, Lambert WM, Watkins R, Giashuddin S, Huang SJ, Oxelmark E, Arju R, Hochman T, Goldberg JD, Schneider RJ, Reiz LF, Soares FA, Logan SK, Garabedian MJ.

Cancer Res. 2010 Nov 1;70(21):8446-56. doi: 10.1158/0008-5472.CAN-10-1590. Epub 2010 Sep 16.

6.

Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2.

Tan S, Ding K, Li R, Zhang W, Li G, Kong X, Qian P, Lobie PE, Zhu T.

Breast Cancer Res. 2014 Apr 15;16(2):R40. doi: 10.1186/bcr3644.

7.

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.

Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R.

Breast Cancer Res. 2010;12(3):R40. doi: 10.1186/bcr2594. Epub 2010 Jun 22.

8.

Global profiling of prolactin-modulated transcripts in breast cancer in vivo.

Sato T, Tran TH, Peck AR, Liu C, Ertel A, Lin J, Neilson LM, Rui H.

Mol Cancer. 2013 Jun 12;12:59. doi: 10.1186/1476-4598-12-59.

9.

Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.

Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA.

Breast Cancer Res Treat. 2012 Sep;135(2):415-32. doi: 10.1007/s10549-012-2164-8. Epub 2012 Jul 24.

10.

Expression and clinical significance of estrogen-regulated long non-coding RNAs in estrogen receptor α-positive ovarian cancer progression.

Qiu JJ, Ye LC, Ding JX, Feng WW, Jin HY, Zhang Y, Li Q, Hua KQ.

Oncol Rep. 2014 Apr;31(4):1613-22. doi: 10.3892/or.2014.3000. Epub 2014 Jan 27.

PMID:
24481591
11.

Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.

Lu Y, You M, Ghazoui Z, Liu P, Vedell PT, Wen W, Bode AM, Grubbs CJ, Lubet RA.

Cancer Prev Res (Phila). 2013 Nov;6(11):1151-61. doi: 10.1158/1940-6207.CAPR-13-0126. Epub 2013 Sep 25.

12.

The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer.

Yamamura S, Matsumura N, Mandai M, Huang Z, Oura T, Baba T, Hamanishi J, Yamaguchi K, Kang HS, Okamoto T, Abiko K, Mori S, Murphy SK, Konishi I.

Int J Cancer. 2012 Jan 1;130(1):20-8. doi: 10.1002/ijc.25961. Epub 2011 Apr 18.

13.

Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer.

Andruska N, Zheng X, Yang X, Helferich WG, Shapiro DJ.

Oncogene. 2015 Jul;34(29):3760-9. doi: 10.1038/onc.2014.292. Epub 2014 Sep 29.

14.

Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth.

Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, Bénès V, Roché H, Dalenc F, Auboeuf D, Millevoi S, Vagner S.

Cancer Res. 2009 Nov 1;69(21):8332-40. doi: 10.1158/0008-5472.CAN-09-2206. Epub 2009 Oct 13.

15.
16.

Differential utilization of nuclear and extranuclear receptor signaling pathways in the actions of estrogens, SERMs, and a tissue-selective estrogen complex (TSEC).

Madak-Erdogan Z, Gong P, Katzenellenbogen BS.

J Steroid Biochem Mol Biol. 2016 Apr;158:198-206. doi: 10.1016/j.jsbmb.2015.12.008. Epub 2015 Dec 12.

PMID:
26689478
17.

Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.

Chen B, Gajdos C, Dardes R, Kidwai N, Johnston SR, Dowsett M, Jordan VC.

Int J Oncol. 2005 Aug;27(2):327-35.

PMID:
16010412
18.

Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.

Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP.

Gynecol Oncol. 2007 Sep;106(3):461-8. Epub 2007 Jul 10.

PMID:
17624412
19.

The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients.

Heublein S, Mayr D, Vrekoussis T, Friese K, Hofmann SS, Jeschke U, Lenhard M.

PLoS One. 2013 Aug 9;8(8):e71791. doi: 10.1371/journal.pone.0071791. eCollection 2013.

20.

Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.

Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM.

Clin Cancer Res. 2012 Nov 1;18(21):5911-23. doi: 10.1158/1078-0432.CCR-12-1257. Epub 2012 Aug 15.

Supplemental Content

Support Center